Biotechnology - Genomic and Proteomics/Give an overall picture of the BGP field: Difference between revisions
Jump to navigation
Jump to search
Line 34: | Line 34: | ||
* Product | * Product | ||
** develop a new product (Phillips, "Biotech Business Models") | ** develop a new product (Phillips, "Biotech Business Models") | ||
** RIPCO (Royalty-Income Pharmaceutical Company) | ** RIPCO (Royalty-Income Pharmaceutical Company) - develop a new product and license to a larger company in exchange for royalty on sales (Pareras, "Biotech Business Models") | ||
*** large potential customer bases and the sooner it can be brought to market, the better | *** large potential customer bases and the sooner it can be brought to market, the better | ||
** FIPCO (Fully Integrated Pharmaceutical Company) | ** FIPCO (Fully Integrated Pharmaceutical Company) - develop new product and bring it to market yourself (Pareras, "Biotech Business Models") | ||
*** much easier to accomplish if you have many products with which to diversify risk | *** much easier to accomplish if you have many products with which to diversify risk | ||
** NRDO (No Research, Development Only) | ** NRDO (No Research, Development Only) - buy a 'discarded' drug from a pharmaceutical company and develop it to the point of bringing it to market. Key that you be able to develop the drug in very efficient way, so as to make it profitable (Pareras, "Biotech Business Models") | ||
* Vertical | * Vertical | ||
** early concept to market (Phillips, "Biotech Business Models") | ** early concept to market (Phillips, "Biotech Business Models") |
Revision as of 17:52, 13 March 2009
Give an overall picture of the field.
How was this field born and how is it evolving?
Timeline
- 1953, Crick and Watson discover DNA at Stanford
- 1973, rDNA (insertion of foreign gene between two ends of an existing gene) produced at Stanford (Acharya pp. 2)
- 1970's and 1980's âÃì proliferation of private biotech firms
- 1971, Cetus founded
- 1976, Genentech founded. First firm to use rDNA technology (Acharya pp. 4)
- 1982, first rDNA product, human insulin, approved in US (Acharya pp. 4)
- 1980's firms grow through heavy outside investment
- easy financing for firms that chose to go public (Acharya pp. 2)
- 1980's, outside US, pressure to subsidize public-private partnerships for Biotech research (Acharya pp. 3)
- 1987, stock market crash and larger recession push small biotech firms to merge into larger multinational companies
- 1990, Genentech merges with Hoffman LaRouch to become largest example of this new sort of firm (Acharya pp. 3)
- 1993, only 14 biopharmaceutical companies record profits (Acharya pp. 5)
- 1995, Glaxo-Wellcome merge, forming one of world's largest pharma companies
Causes and Culture
- Biotech industry emerged from Bay area in 1960's
- Stanford's biochemistry and virology (later molecular biology) departments expanded aggressively during this time (Penhoet pp. 6)
- Bill Rutter, chairman of UCSF's Biochemistry and Biophysics department . His work ethic became the model for the industry (Penhoet pp. 7)
- Herb Boyer, Bob Swanson start Genentech in the mid-1970's
- first private biotech firm
- later followed by Cetus, Chiron (Penhoet pp. 8)
- Venture Capital firms already existed to support emerging Silicon Valley, came in to support Biotech ventures as well (Penhoet pp. 8)
- Open attitude towards IP: belief early on that innovation would be sustained, so academics continued to publish their findings, even when working with private companies (Penhoet pp. 8-9)
What are the main business models?
- Platform
- develop technology platform (e.g. research method) and license it to other companies (Phillips, "Biotech Business Models")
- Most viable model since the Biotech bust of 2001
- Broad patent protection will help this sort of business model (Pareras, "Biotech Business Models")
- Product
- develop a new product (Phillips, "Biotech Business Models")
- RIPCO (Royalty-Income Pharmaceutical Company) - develop a new product and license to a larger company in exchange for royalty on sales (Pareras, "Biotech Business Models")
- large potential customer bases and the sooner it can be brought to market, the better
- FIPCO (Fully Integrated Pharmaceutical Company) - develop new product and bring it to market yourself (Pareras, "Biotech Business Models")
- much easier to accomplish if you have many products with which to diversify risk
- NRDO (No Research, Development Only) - buy a 'discarded' drug from a pharmaceutical company and develop it to the point of bringing it to market. Key that you be able to develop the drug in very efficient way, so as to make it profitable (Pareras, "Biotech Business Models")
- Vertical
- early concept to market (Phillips, "Biotech Business Models")